Kamal Haasan Vishwaroopam controversy News
Suriya’s Singam 2 and Mani Ratnam’s Kadal in trouble for hurting religious sentiments
It seems films are becoming easy targets these days. Close on the heels of Kamal Haasan’s Vishwaroopam facing hurdles, two more movies are in a similar situation
While Mani Ratnam’s Kadal, starring Gautham Karthik and Thulasi Nair, which hit the screens Friday last, has earned the wrath of a Christian group, superstar Suriya’s upcoming film Singam 2 now faces opposition from a Muslim association. Click here to read more
Salman Khan found Kamal Haasan’s Vishwaroop on par with Hollywood standards!
Salman Khan attended the premiere of Kamal Hassan’s controversial film. The Dabangg star is certainly happy with the Southern superstar’s work
Kamal Haasan is beaming with happiness. After all Bollywood’s Dabangg superstar Salman Khan found his film Vishwaroop, the Hindi version of his controversial film Vishwaroopam, on a par with international standards. “He (Salman) liked it immensely. He thinks it is of Hollywood standards. He liked everything about it,” Haasan said at a special screening of the film. Click here to read more
Vishwaroopam ban impact: Kamal Haasan suffers Rs 60-crore loss!
It’s not only been an emotional roller coaster ride, financially too, the actor has taken a huge hit
It’s not been an emotional turmoil alone. The multi-faceted Kamal Haasan has incurred financial strain as well. He is now looking at a humongous loss of anywhere between Rs 30 crores to Rs 60 crores Click here to read more
Will Kamal Haasan survive the Vishwaroopam crisis?
Tied up in controversies, financial depression and emotional exhaustion – Kamal Haasan is going through tremendous pressure. Will the making of Vishwaroopam finally be worth it? Will he really leave his home State? Tarot explores all this…
The Page of Cups and the Eight Swords are clear representatives of those who are ignorant through naivety and those who wish to restrict society viewpoints. Such elements will continue to be a cause for concern Click here to read more